Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BNT327 plus platinum-etoposide versus atezolizumab plus platinum-etoposide in first-line extensive-stage small-cell lung cancer
2024-515765-34-00Phase 3Suspended
- Sponsor
- BioNTech SE
- Start
- Feb 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of pumitamig, atezolizumab, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC) (2 arms), sponsored by BioNTech SE. Primary endpoint: Overall survival. Started Feb 2026; status: suspended.
02
Drugs
pumitamigatezolizumabetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-515765-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515765-34-00.